Rob Schrepfer

Robert Schrepfer’s career in healthcare and investing has spanned 30+ years. He joined the 1315 team in 2023, bringing his operations and financial experience to innovative companies primed for growth. Rob is currently on the board of Medivant Healthcare, a sterile injectable company focused on developing and commercializing drug shortage products.

In 2021 Rob joined McKesson where he serves today as Division President, leading the Generics, OTC and Consumer Goods categories.  Prior to McKesson he was a member of the Executive Operating team and the SVP of Business Development, Specialty Sales and Contract Manufacturing at ANI Pharmaceuticals (Nasdaq: ANIP).  As a founding shareholder, he joined the leadership team in 2013 from the Board of Directors. During his eight years with ANI, Rob established and executed a corporate growth strategy that generated 15x equity returns as the market cap grew from $60 million to $1B+.  He established and managed a $100 million commercial Brand business, led the acquisition of Novitium Pharma and Wellspring Pharma and, across 20+ transactions, grew the commercial portfolio from six to 60+ products and established a generic pipeline of 200+ molecules.

Previously, he served as Managing Director at Healthcare Value Capital, a healthcare investment company where he managed the firm’s private investments, serving on numerous boards, as well as a long/short equity fund focused on healthcare services, devices and specialty pharmaceuticals.  Prior to this he was Managing Director at Bear Stearns, providing sell-side research coverage of Brand, Specialty and Generic pharmaceutical companies.  In addition, Rob has founded several healthcare businesses including National Healthcare Analysis Group, Chesapeake Therapeutics and TLC Therapeutics and served as Clinical Director and Director of Outcomes and Research for a private physical therapy practice.  He earned an MBA from Duke University, an MS in Physical Therapy from the University of Indianapolis and a BA from the University of Kansas.